Metabolic agents such as GLP-1 receptor agonists (liraglutide, semaglutide) and THR-β agonists (resmetirom) are now front-line options due to their ability to improve insulin sensitivity, reduce hepatic steatosis, and achieve histologic resolution. This evidence concerns the gene INS and Hepatic steatosis.